title: Metabolic monitoring and management among clozapine users.
abstract: OBJECTIVE
  To assess, among clozapine users, the rates of monitoring, presence and treatment of metabolic syndrome and its components.
  
  
  METHODS
  A chart review was conducted of all clozapine users who were followed up in community mental health clinics at two Metro South Health Hospitals over a 1-year period. Metabolic syndrome was diagnosed according to the International Diabetes Federation criteria.
  
  
  RESULTS
  We included 251 clozapine users. Only 43.4% (109/251) had data collected for all five metabolic syndrome parameters. Among these people, 45.0% (49/109) met criteria for metabolic syndrome, while 61.2% (30/49) of those with metabolic syndrome were offered appropriate treatments. Correspondence with primary care providers occurred in only 18.7% ( n = 47). Non-pharmacological interventions, such as motivational interviewing and education about healthy lifestyle alternatives, occurred in 49.8% ( n = 125).
  
  
  CONCLUSIONS
  There is growing awareness of the importance of metabolic monitoring, however, there remain specific gaps in the collaborative work among mental health services, primary care providers and clozapine users, to ensure appropriate physical health interventions.
authors: Registrar, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia.
authors: Grace
authors: G
authors: Tso
authors: Registrar, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia.
authors: Puja
authors: P
authors: Kumar
authors: Registrar, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, Australia, and; District General Hospital Trincomalee, Trincomalee, Sri Lanka.
authors: Thilini
authors: T
authors: Jayasooriya
authors: Professor, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, and; University of Queensland School of Medicine, Brisbane, QLD, Australia.
authors: Steve
authors: S
authors: Kisely
authors: Associate Professor, Psychiatry, Metro South Addiction and Mental Health Service, Brisbane, QLD, and; University of Queensland School of Medicine, Brisbane, QLD, Australia.
authors: Dan
authors: D
authors: Siskind
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001315:Australia; D003024:Clozapine / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology*; D008875:Middle Aged; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine
keywords: antipsychotic; clozapine; metabolic monitoring; metabolic syndrome; psychosis